 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...4142434445464748495051...235236» |
- | New P3 trial, Circulating tumor DNA, Epigenetic controller: Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer (clinicaltrials.gov) - Jul 20, 2023
P3, N=340, Recruiting, Sponsor: Fudan University
- | Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, Real-world evidence, Real-world, Metastases: Impact of encorafenib on survival of patients with BRAF-mutant metastatic colorectal cancer in a real-world setting. (Pubmed Central) - Jul 19, 2023
Patients with BRAF-mutated mCRC benefit from the addition of an antibody to first-line chemotherapy. Further-line treatment including a BRAF inhibitor has a dramatic impact on survival.
- | 5-fluorouracil / Generic mfg.
Journal, Metastases: Baseline Expression of Exosomal miR-92a-3p and miR-221-3p Could Predict the Response to First-Line Chemotherapy and Survival in Metastatic Colorectal Cancer. (Pubmed Central) - Jul 18, 2023
Thirty-one metastatic colorectal cancer patients were selected before receiving first-line irinotecan- or oxaliplatin-based chemotherapy...In line with these findings, we conclude that the increased baseline exosomal expression of miR-92a-3p and miR-221-3p seems to predict a lack of response to chemotherapy and lower OS. However, further prospective studies on more patients are needed before drawing practice-changing conclusions.
- || leucovorin calcium / Generic mfg.
Review, Journal: Hypomyelination caused by a novel homozygous pathogenic variant in FOLR1: complete clinical and radiological recovery with oral folinic acid therapy and review of the literature. (Pubmed Central) - Jul 18, 2023
Moreover, through the report of these patients along with review of the literature, we provide information about the natural history of the disease with comparison of treatment effects at different stages of disease progression. This report also reinforces the importance of universal access to genetic testing to ensure prompt diagnoses for treatable disorders.
- | irinotecan / Generic mfg.
Journal: MACC1 and Gasdermin-E (GSDME) regulate the resistance of colorectal cancer cells to irinotecan. (Pubmed Central) - Jul 18, 2023
This report also reinforces the importance of universal access to genetic testing to ensure prompt diagnoses for treatable disorders. Consistently, by analyzing CRC patients who received FOLFIRI (Fluorouracil
- || 5-fluorouracil / Generic mfg.
Clinical, Journal: Short-term outcomes of Early versus conventional adjuvant chemotherapy in stage III colon cancer: randomized clinical trial. (Pubmed Central) - Jul 17, 2023
Consistently, by analyzing CRC patients who received FOLFIRI (Fluorouracil Adjuvant chemotherapy can be safely initiated 2 weeks after surgery with toxicity and quality of life comparable to conventional adjuvant chemotherapy for stage III colon cancer.
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Survival benefit of preoperative hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin followed by hepatectomy for hepatocellular carcinoma. (Pubmed Central) - Jul 17, 2023
Preoperative FOLFOX-HAIC is associated with a longer survival outcome for HCC patients. The novel nomogram efficiently predicted the OS of patients who underwent preoperative FOLFOX-HAIC.
- ||| Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
Journal, Adverse events: Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials. (Pubmed Central) - Jul 17, 2023
Most of chemotherapy-related AEs (except for HFS and neuropathy) reach the highest level in the first cycles, then decrease, probably due to their active clinical management. Transition to maintenance allows relief from most AEs, especially with bevacizumab-based regimens, while anti-EGFR-related AEs may persist.
- || Cyramza (ramucirumab) / Eli Lilly
P2 data, Journal, Metastases: Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). (Pubmed Central) - Jul 17, 2023
P2
The addition of RAM to FOLFIRINOX did not significantly impact PFS or OS. The combination was well tolerated (Funded by Eli Lilly; ClinicalTrials.gov number, NCT02581215).
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial primary completion date, Metastases: AMBITION: Neoadjuvant Therapy for Locally Advanced Colon Cancer (clinicaltrials.gov) - Jul 17, 2023
P2, N=64, Recruiting, Sponsor: Zhejiang University
The combination was well tolerated (Funded by Eli Lilly; ClinicalTrials.gov number, NCT02581215). Trial primary completion date: Mar 2023 --> Dec 2024
- | Erbitux (cetuximab) / Eli Lilly
New P3 trial: Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM (clinicaltrials.gov) - Jul 17, 2023
P3, N=250, Not yet recruiting, Sponsor: Fudan University
- | Avastin (bevacizumab) / Roche
Journal, Real-world evidence, Real-world: Evaluation and Comparison of Real-World Databases for Conducting Research in Patients With Colorectal Cancer. (Pubmed Central) - Jul 16, 2023
Compared with other databases, GENIE-BPC had the youngest patients with CRC with the most advanced disease and the largest proportion of patients receiving treatment. Investigators should consider adjustments when extrapolating results from clinico-genomic databases to the general CRC population.
- | Vectibix (panitumumab) / Amgen, Takeda
Journal, HEOR, Metastases: Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. (Pubmed Central) - Jul 16, 2023
P2
Maintenance therapy improves HRQOL dimensions that initially deteriorated during induction therapy while stabilising HRQOL in other dimensions. The addition of Pmab to FU/FA as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer prolongs progression-free survival without negative impact on HRQOL.
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data: Optimal maintenance strategy following FOLFOX + anti-EGFR in RAS WT mCRC: individual patient data pooled analysis of 4 clinical trials @OncologyAdvance https://t.co/m0C5Z9Vc3S 👉Low evidence, overall FU/LV + anti-EGFR preferred maintenance, stop & go stillan option @myESMO… https://t.co/VaNKlHpNf3 (Twitter) - Jul 16, 2023
- | 5-fluorouracil / Generic mfg.
Journal, Metastases: Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma. (Pubmed Central) - Jul 14, 2023
Male gender, ECOG-PS 0/1, the FFX regimen, and NLR > 4.15 were independent predictors of OS. PFS-L2 and OS-L2 were favorably impacted by L1 with FFX.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Journal, Metastases: Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials. (Pubmed Central) - Jul 14, 2023
This pooled analysis including four randomised phase II supports the use of 5-FU/LV plus anti-EGFR as the preferred maintenance regimen. Data provide rational for a more individualised maintenance treatment approach based on tumour and patients features.
- | 5-fluorouracil / Generic mfg.
Journal: Co-delivery of three synergistic chemotherapeutics in a core-shell nanoscale coordination polymer for the treatment of pancreatic cancer. (Pubmed Central) - Jul 14, 2023
Here, we report a core-shell nanoscale coordination polymer (NCP) nanoparticle co-delivering a potent and synergistic combination of oxaliplatin, gemcitabine, and SN38 (OGS), for the treatment of pancreatic cancer in mouse models...OGS treatment achieved 75-91% tumor growth inhibition and prolonged mouse survival by 1.6- to 2.8-folds while minimizing systemic toxicities such as neutropenia, hepatotoxicity, and renal toxicity. This work uncovers a novel and clinically relevant nanomedicine strategy to co-deliver synergistic combination chemotherapies for difficult-to-treat cancers.
- | Vectibix (panitumumab) / Amgen, Takeda
Journal, Metastases: Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212). (Pubmed Central) - Jul 14, 2023
Female patients did not show the same benefit while experiencing higher rates of adverse events. Our results support the development of sex-specific protocols.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, Surgery: Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. (Pubmed Central) - Jul 14, 2023
Among PDAC patients who underwent surgery following neoadjuvant FOLFIRINOX, adjuvant chemotherapy may be associated with improved survival. Randomized studies should be conducted to validate this finding.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
P2 data, Retrospective data, Journal, Surgery: One-Week versus Two-Week Chemoradiotherapy Followed by Curative Surgery in Rectal Cancer: Long-Term Comparative Pooled Analysis of Two Prospective Multicenter Phase II Trials. (Pubmed Central) - Jul 14, 2023
Both 1- and 2-week schedules of CRT showed favorable survival outcomes after 7 years of follow-up. But, 2-week course achieved more increased tumor response and decreased acute toxicity than 1-week course.
- | oxaliplatin / Generic mfg.
Preclinical, Journal: Isolinderalactone Resistance to the Liver Injury Induced by Oxaliplatin in Rats through Inhibiting IL-6/STAT3 Signal Pathway. (Pubmed Central) - Jul 14, 2023
But, 2-week course achieved more increased tumor response and decreased acute toxicity than 1-week course. ILL resistance to liver injury through inhibiting IL-6/STAT3 signal pathway.
- |||||||||| irinotecan hydrochloride liposome injection (HR070803) / Jiangsu Hengrui Pharma
New P2/3 trial: A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer (clinicaltrials.gov) - Jul 14, 2023
P2/3, N=606, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Retrospective data, Review, Journal, Real-world evidence, Real-world, Metastases: Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis. (Pubmed Central) - Jul 13, 2023
There were 12 different types of 'planned' dose modification in FOLFIRINOX ranging 75-100% oxaliplatin, 75-100% irinotecan, 0-100% 5-fluorouracil (5-FU) bolus, and 75-133% 5-FU continuous injection...The pattern of dose modification was not consistent across studies, and there was a significant gap between the 'planned' and 'actual' doses. Modified FOLFIRINOX showed similar efficacy to the standard regimen with reduced incidence of febrile neutropenia.
- | Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: BASKET?: mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC (clinicaltrials.gov) - Jul 13, 2023
P2, N=42, Recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
Modified FOLFIRINOX showed similar efficacy to the standard regimen with reduced incidence of febrile neutropenia. Trial primary completion date: May 2022 --> May 2024
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Jul 13, 2023
P1/2, N=49, Active, not recruiting, Sponsor: David Bajor
Trial primary completion date: May 2022 --> May 2024 Trial completion date: Apr 2024 --> Oct 2024 | Trial primary completion date: Apr 2023 --> Oct 2023
- | Mektovi (binimetinib) / Pfizer
Trial initiation date: Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (clinicaltrials.gov) - Jul 12, 2023
P2, N=66, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Apr 2024 --> Oct 2024 | Trial primary completion date: Apr 2023 --> Oct 2023 Initiation date: Dec 2022 --> Sep 2023
- | Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Metastases: PRODIGE 59 - DURIGAST: Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jul 12, 2023
P2, N=107, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Initiation date: Dec 2022 --> Sep 2023 Trial completion date: Feb 2023 --> Sep 2023
- | Enrollment change, Trial withdrawal: Phase ? Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE (clinicaltrials.gov) - Jul 12, 2023
P2, N=0, Withdrawn, Sponsor: Sun Yat-sen University
Trial completion date: Feb 2023 --> Sep 2023 N=100 --> 0 | Recruiting --> Withdrawn
- | Opdivo (nivolumab) / BMS
Enrollment open: A022102: mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma (clinicaltrials.gov) - Jul 12, 2023
P3, N=382, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
N=100 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
Enrollment closed: REGONIVOCTx: Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy (clinicaltrials.gov) - Jul 12, 2023
P1/2, N=30, Active, not recruiting, Sponsor: National Cancer Center Hospital East
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || TTX-080 / Tizona Therap
Enrollment closed, Trial primary completion date, Monotherapy: TTX-080-001: TTX-080 HLA-G Antagonist in Subjects with Advanced Cancers (clinicaltrials.gov) - Jul 12, 2023
P1a/1b, N=240, Active, not recruiting, Sponsor: Tizona Therapeutics, Inc
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2023 --> Dec 2023
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., docetaxel / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: GASTFOX: PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA (clinicaltrials.gov) - Jul 12, 2023
P3, N=507, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2023 --> Dec 2023 Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Apr 2023
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal, Metastases: Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer. (Pubmed Central) - Jul 12, 2023
Modified fluorouracil/leucovorin/irinotecan/oxaliplatin (FOLFIRINOX) regimen (mFOLFIRINOX), comprised of fluorouracil, leucovorin, irinotecan and oxaliplatin, is the first-line standard chemotherapy in patients with advanced pancreatic cancer...The occurrence of any grade 3 to 4 toxicity was similar in the two groups. For locally advanced or metastatic pancreatic cancer patients, the SOXIRI regimen had similar efficacy and controllable safety compared with the mFOLFIRINOX regimen.
- leucovorin calcium / Generic mfg., levetiracetam / Generic mfg., desmopressin / Generic mfg.
Unexplained cerebrospinal fluid findings in GABA transaminase deficiency (Exhibitions Hall (ICC)) - Jul 11, 2023 - Abstract #SSIEM2023SSIEM_615;
It is of note that central DI has been described before in this very rare disorder. Further studies are required to understand the CSF biochemistry.
- leucovorin calcium / Generic mfg.
First Late-Onset Cerebral Folate Transporter Deficiency with a Novel Mutation Mimicking SSPE and Wilson (Exhibitions Hall (ICC)) - Jul 11, 2023 - Abstract #SSIEM2023SSIEM_469;
Further studies are required to understand the CSF biochemistry. The extremely low CSF 5-methiltetrahyrofolate level confirmed the disease, so he was treated orally with calcium folinate replacement...Even though the EEG showed SSPE or the brain MRI pathologies indicated disorders with metal deposition such as Wilson
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical: Tough case! And challenging as well How about FOLFIRI? If considered second line to FOLFOX for pancreatic-biliary origin. Liposomal iri as a second line pancreatic origin Would obtain BRCA for sure, combo of prost ca+ pancreatic-biliary origin pushes for it. (Twitter) - Jul 11, 2023
- | Journal: Cutoff value of IC for drug sensitivity in patient-derived tumor organoids in colorectal cancer. (Pubmed Central) - Jul 10, 2023
We established PDTOs and performed a drug test in 277 samples from 242 CRC patients who received FOLFOX or XELOX chemotherapy...Moreover, this value distinguished groups of patients with significant differences in survival benefit. Our study is the first to define the IC cutoff value for the PDTO drug test to effectively distinguish CRC patients with chemosensitivity or nonsensitivity and predict survival benefits.
- | ropidoxuridine (IPdR) / Shuttle Pharma, National Cancer Institute
Journal: A case report of typhlitis during novel use of ropidoxuridine-capecitabine-radiotherapy for treatment-na (Pubmed Central) - Jul 10, 2023
P1
The report also presents the rare complication of sigmoid typhlitis as a treatment-attributed adverse event. In this case, a ropidoxuridine-capecitabine combination was used as an investigational radiosensitizing treatment now with a narrower future clinical development pathway.
- ||| Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
P3 data, Journal: First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. (Pubmed Central) - Jul 10, 2023
P3
In patients with initially unresectable colorectal cancer liver metastases, FOLFOXIRI-bevacizumab was the preferred treatment in patients with a right-sided or RAS or BRAF mutated primary tumour. In patients with a left-sided and RAS and BRAF wild-type tumour, the addition of panitumumab to FOLFOX or FOLFIRI showed no clinical benefit over bevacizumab, but was associated with more toxicity.
- |||| Metastases: Here is our international collaborative work on FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer @AnnSurgOncol @SocSurgOnc @SSATNews @FlavioRochaMD https://t.co/4ALnMZQuI3 (Twitter) - Jul 8, 2023
- | 5-fluorouracil / Generic mfg.
Observational data, Journal, Metastases: Second-line Chemotherapy in Advanced Gastric Cancer: Taxanes versus 5-FU-Based Treatment. (Pubmed Central) - Jul 8, 2023
The superiority of chemotherapy regimens to each other could not be demonstrated. However, the second-line treatment demonstrated clear superiority over the best
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial primary completion date, Combination therapy, Metastases: Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: (clinicaltrials.gov) - Jul 7, 2023
P2, N=28, Recruiting, Sponsor: Nelson Yee
However, the second-line treatment demonstrated clear superiority over the best Trial primary completion date: Mar 2023 --> Nov 2023
- |||| cabiralizumab (BMS-986227) / Ono Pharma, BMS, Opdivo (nivolumab) / BMS
Trial completion, Trial completion date, Trial primary completion date: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Jul 7, 2023
P2, N=206, Completed, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Mar 2023 --> Nov 2023 Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Jun 2023 | Trial primary completion date: Oct 2023 --> Jun 2023
- leucovorin calcium / Generic mfg.
Cerebral folate deficiency due to DHFR mutation (Exhibitions Hall (ICC)) - Jul 6, 2023 - Abstract #SSIEM2023SSIEM_197;
Folinic acid was subsequently started at 1 year of age with seizure control, although his developmental evaluation revealed progressive deterioration... The early intervention in our second child preceding the neurological symptoms, gives us hope for a better outcome
- | Graspa (eryaspase) / PHAXIAM Therap
Trial completion date, Trial primary completion date: Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Jul 6, 2023
P1, N=19, Active, not recruiting, Sponsor: Georgetown University
The early intervention in our second child preceding the neurological symptoms, gives us hope for a better outcome Trial completion date: Dec 2024 --> Dec 2023 | Trial primary completion date: May 2023 --> Dec 2022
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma (clinicaltrials.gov) - Jul 6, 2023
P2, N=63, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Trial completion date: Dec 2024 --> Dec 2023 | Trial primary completion date: May 2023 --> Dec 2022 Trial completion date: Sep 2025 --> Oct 2023 | Trial primary completion date: Jun 2023 --> Oct 2023
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New trial, Pan tumor, Biopsy: An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCC (clinicaltrials.gov) - Jul 6, 2023
P=N/A, N=165, Recruiting, Sponsor: Xiangya Hospital of Central South University
- | Stivarga (regorafenib) / Bayer
Trial completion date, Combination therapy, Metastases: FOLFIRINOX-R: Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer (clinicaltrials.gov) - Jul 5, 2023
P1/2, N=13, Active, not recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Trial completion date: Sep 2025 --> Oct 2023 | Trial primary completion date: Jun 2023 --> Oct 2023 Trial completion date: Dec 2023 --> Oct 2024
- | Trial completion date, Trial primary completion date, Combination therapy: Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Jul 5, 2023
P1, N=38, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Dec 2023 --> Oct 2024 Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024